Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Valsartan recalled?

Yes — there is an active recall. 83 ongoing FDA recalls mention Valsartan (138 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Valsartan. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Valsartan recalls on record

none so far in 2026; 138 on record, newest first
Class II · Moderate risk

Amlodipine and Valsartan Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.

Ongoing Nitrosamine impurity Mylan Pharmaceuticals Inc. NDC 0378-1721-93 D-0311-2019
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1145-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1144-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1143-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1142-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1141-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1136-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1135-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1134-2018
Class II · Moderate risk

Valsartan Tablets USP 320 mg

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Preferred Pharmaceuticals, Inc NDC 68788-6882-9 D-1107-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-786-13 D-1133-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-785-15 D-1132-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-784-15 D-1131-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-783-15 D-1130-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-363-90 D-1106-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-362-90 D-1105-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-361-90 D-1104-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-360-30 D-1103-2018
Class II · Moderate risk

Valsartan 320 mg Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity RemedyRepack Inc. NDC 61786-0793-19 D-1102-2018